WO2000005265A3 - Anti-crr2 antibodies and methods of use therefor - Google Patents
Anti-crr2 antibodies and methods of use therefor Download PDFInfo
- Publication number
- WO2000005265A3 WO2000005265A3 PCT/US1999/016452 US9916452W WO0005265A3 WO 2000005265 A3 WO2000005265 A3 WO 2000005265A3 US 9916452 W US9916452 W US 9916452W WO 0005265 A3 WO0005265 A3 WO 0005265A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- crr2
- methods
- receptor
- use therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT99937353T ATE446973T1 (en) | 1998-07-23 | 1999-07-22 | ANTI-CCR2 ANTIBODIES AND THEIR USE |
CA2336250A CA2336250C (en) | 1998-07-23 | 1999-07-22 | Anti-ccr2 antibodies and methods of use therefor |
JP2000561221A JP4057243B2 (en) | 1998-07-23 | 1999-07-22 | Anti-CCR2 antibody and method of use thereof |
AU52208/99A AU764825B2 (en) | 1998-07-23 | 1999-07-22 | Anti-CCR2 antibodies and methods of use therefor |
DE69941598T DE69941598D1 (en) | 1998-07-23 | 1999-07-22 | ANTI-CCR2 ANTIBODIES AND THEIR USE |
EP99937353A EP1098908B1 (en) | 1998-07-23 | 1999-07-22 | Anti-ccr2 antibodies and methods of use therefor |
AU2003213475A AU2003213475B2 (en) | 1998-07-23 | 2003-07-14 | Anti-CCR2 antibodies and methods of use therefor |
AU2006206064A AU2006206064B2 (en) | 1998-07-23 | 2006-09-01 | Anti-CCR2 antibodies and methods of use therefor |
AU2009200820A AU2009200820A1 (en) | 1998-07-23 | 2009-03-02 | Anti-CCR2 antibodies and methods of use therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/121,781 | 1998-07-23 | ||
US09/121,781 US6312689B1 (en) | 1998-07-23 | 1998-07-23 | Anti-CCR2 antibodies and methods of use therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000005265A2 WO2000005265A2 (en) | 2000-02-03 |
WO2000005265A3 true WO2000005265A3 (en) | 2000-04-27 |
Family
ID=22398750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/016452 WO2000005265A2 (en) | 1998-07-23 | 1999-07-22 | Anti-crr2 antibodies and methods of use therefor |
Country Status (9)
Country | Link |
---|---|
US (16) | US6312689B1 (en) |
EP (2) | EP1098908B1 (en) |
JP (3) | JP4057243B2 (en) |
AT (1) | ATE446973T1 (en) |
AU (4) | AU764825B2 (en) |
CA (1) | CA2336250C (en) |
DE (1) | DE69941598D1 (en) |
ES (1) | ES2335948T3 (en) |
WO (1) | WO2000005265A2 (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3532570B2 (en) * | 1994-01-13 | 2004-05-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Mammalian monocyte chemoattractant protein receptor |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6610834B1 (en) * | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
EP1118858A3 (en) * | 2000-01-12 | 2003-07-09 | Pfizer Limited | Assay method |
EP1783227A1 (en) * | 2000-02-03 | 2007-05-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
ATE373719T1 (en) * | 2000-02-03 | 2007-10-15 | Millennium Pharm Inc | HUMANIZED ANTIBODIES AGAINST CCR2 AND METHOD OF USE THEREOF |
AU2004208716B2 (en) * | 2000-02-03 | 2007-01-04 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
GB0004183D0 (en) * | 2000-02-22 | 2000-04-12 | Smithkline Beecham Plc | New use |
WO2001070266A2 (en) * | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
US20030211105A1 (en) * | 2001-05-18 | 2003-11-13 | Murphy William J | Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity |
US7282338B2 (en) | 2001-06-07 | 2007-10-16 | Chemocentryx, Inc. | Cell migration assay |
US7468253B2 (en) * | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
US20040151721A1 (en) * | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
AR037456A1 (en) | 2001-11-30 | 2004-11-10 | Biogen Inc | ANTIBODIES AGAINST MONOCITARY CHEMOTHOTAL PROTEINS |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
MXPA04008937A (en) | 2002-03-15 | 2005-06-17 | Schering Corp | Methods of modulating cd200 receptors. |
US20060030582A1 (en) * | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
JO2479B1 (en) * | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Tetrahydropyranyl cyclopentyl tetrah- ydropyridopyrdine modulators of chemohne receptor activity. |
EP1501507B1 (en) | 2002-04-29 | 2008-05-28 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
US7230008B2 (en) * | 2002-04-29 | 2007-06-12 | Merck & Co, Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
US7285270B2 (en) * | 2002-07-31 | 2007-10-23 | Trustees Of Dartmouth College | Method of reducing neuropathic pain |
SG173922A1 (en) | 2002-11-27 | 2011-09-29 | Incyte Corp | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
US7888479B2 (en) | 2002-11-27 | 2011-02-15 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactric proteins |
CA2521950C (en) * | 2003-04-15 | 2009-11-17 | Merck & Co., Inc. | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
US20050202029A1 (en) * | 2003-10-03 | 2005-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Family of cystatin-related chemoattractant proteins |
CA2529694A1 (en) | 2003-12-10 | 2005-07-07 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
WO2005101838A2 (en) | 2004-04-13 | 2005-10-27 | Incyte Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
WO2005101002A1 (en) * | 2004-04-13 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 2 (ccr2) |
JP2008508253A (en) * | 2004-07-30 | 2008-03-21 | ファイザー・プロダクツ・インク | CCR2-mediated disease or disorder treatment |
AR056142A1 (en) | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
DE102006015341A1 (en) * | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Use of an antibody, which specifically binds to the chemokine receptor 2, for the production of a medicament for the treatment of therapy-refractory multiple sclerosis and/or therapy-refractory rheumatoid arthritis in the subject |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
JP2010505878A (en) * | 2006-10-05 | 2010-02-25 | セントコア・オーソ・バイオテツク・インコーポレーテツド | CCR2 antagonist for the treatment of fibrosis |
AR065369A1 (en) * | 2007-02-19 | 2009-06-03 | Novartis Ag | CICLOHEXIL DERIVATIVES - AMIDA OF ARIL- CARBOXILIC ACID |
CA2714335A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
EP2321351B1 (en) | 2008-08-18 | 2017-11-01 | Pfizer Inc. | Antibodies to ccr2 |
EP2161072A1 (en) * | 2008-09-03 | 2010-03-10 | Gambro Lundia AB | High cut-off hemodialysis membranes for the treatment of chronic hemodialysis patients |
MY152557A (en) | 2008-11-26 | 2014-10-31 | Pfizer | 3-aminocyclopentanecarboxamides as chemokine receptor modulators |
DK3903829T3 (en) | 2009-02-13 | 2023-06-26 | Immunomedics Inc | IMMUNE CONJUGATES WITH AN INTRACELLULAR CLEAVABLE BOND |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US20110038871A1 (en) | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
KR101433487B1 (en) | 2009-09-16 | 2014-08-22 | 콜게이트-파아므올리브캄파니 | Oral care system, kit and method |
IN2012DN01663A (en) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
WO2011078864A1 (en) | 2009-12-23 | 2011-06-30 | Colgate-Palmolive Company | Oral care system |
CN102711554B (en) | 2009-12-23 | 2014-10-29 | 高露洁-棕榄公司 | Oral care system |
US8851779B2 (en) | 2009-12-23 | 2014-10-07 | Colgate-Palmolive Company | Oral care system, kit and method |
RU2560058C2 (en) | 2009-12-23 | 2015-08-20 | Колгейт-Палмолив Компани | Method of oral care |
AU2011341697B2 (en) | 2010-12-15 | 2015-05-28 | Colgate-Palmolive Company | Oral care dispenser |
WO2012114223A1 (en) | 2011-02-25 | 2012-08-30 | Pfizer Limited | A method of treating liver fibrosis |
RU2607038C2 (en) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Antigen-binding proteins |
AR085403A1 (en) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | MONOVALENT PROTEINS THAT JOIN ANTIGENS |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
ES2636679T3 (en) | 2011-06-27 | 2017-10-06 | Université Pierre Et Marie Curie (Paris 6) | CCR2 antagonist peptides |
EP2864358B1 (en) | 2012-06-22 | 2019-08-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
WO2014064192A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction |
HUE057977T2 (en) | 2012-12-13 | 2022-06-28 | Immunomedics Inc | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
JP6422956B2 (en) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Multispecific domain exchange common variable light chain antibody |
MX2016010683A (en) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Disease therapy by inducing immune response to trop-2 expressing cells. |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
WO2015200260A1 (en) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
PL3204018T3 (en) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
US10426251B2 (en) | 2015-02-02 | 2019-10-01 | Colgate-Palmolive Company | Oral care system and oral care material dispenser |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
ES2953441T3 (en) | 2015-06-25 | 2023-11-13 | Immunomedics Inc | Combination of anti-hla-dr or anti-Trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
US10980739B2 (en) | 2016-12-14 | 2021-04-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
JPWO2022239720A1 (en) | 2021-05-10 | 2022-11-17 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019436A1 (en) * | 1994-01-13 | 1995-07-20 | The Regents Of The University Of California | Mammalian monocyte chemoattractant protein receptors |
WO1997031949A1 (en) * | 1996-03-01 | 1997-09-04 | Consejo Superior De Investigaciones Cientificas | Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
TW212184B (en) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5182366A (en) | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
US5543503A (en) | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US5437214A (en) * | 1992-05-22 | 1995-08-01 | Makita Corporation | Miter saw |
US5508384A (en) | 1992-09-10 | 1996-04-16 | New York University | Polypeptide derived from a popamine receptor, and compositions and methods thereof |
WO1994009128A1 (en) | 1992-10-22 | 1994-04-28 | Mallinckrodt Medical, Inc. | Therapeutic treatment for inhibiting vascular restenosis |
AU5732694A (en) | 1992-12-01 | 1994-06-22 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
US5468707A (en) | 1992-12-01 | 1995-11-21 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Coordination catalyst systems |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
DE4332256C1 (en) | 1993-09-22 | 1995-03-09 | Lipp Martin Dr Dr Habil | Monoclonal antibodies against leukocyte-specific G protein-coupled receptors |
US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
JPH09282886A (en) * | 1996-01-19 | 1997-10-31 | Sgs Thomson Microelectron Inc | Circuit and method for tracking of start of writing operation to memory cell |
US5864696A (en) * | 1996-01-19 | 1999-01-26 | Stmicroelectronics, Inc. | Circuit and method for setting the time duration of a write to a memory cell |
US7115379B1 (en) * | 1996-01-24 | 2006-10-03 | Schering Corporation | Anti-mammalian CX3C cytokine antibodies |
US5657277A (en) * | 1996-04-23 | 1997-08-12 | Micron Technology, Inc. | Memory device tracking circuit |
AU735460B2 (en) | 1996-06-14 | 2001-07-12 | Aaron Diamond Aids Research Center, The | Uses of a chemokine receptor for inhibiting HIV-1 infection |
EP0969853A4 (en) | 1997-03-25 | 2004-07-14 | Massachusetts Inst Technology | Modulation of vascular healing by inhibition of leukocyte adhesion and function |
WO1998044953A1 (en) | 1997-04-04 | 1998-10-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US5858089A (en) * | 1997-08-26 | 1999-01-12 | Martinovic; Zoran | Corn buttering tool |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) * | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
US20040151721A1 (en) * | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
-
1998
- 1998-07-23 US US09/121,781 patent/US6312689B1/en not_active Expired - Lifetime
-
1999
- 1999-07-22 JP JP2000561221A patent/JP4057243B2/en not_active Expired - Lifetime
- 1999-07-22 CA CA2336250A patent/CA2336250C/en not_active Expired - Lifetime
- 1999-07-22 US US09/359,193 patent/US6352832B1/en not_active Expired - Lifetime
- 1999-07-22 AU AU52208/99A patent/AU764825B2/en not_active Expired
- 1999-07-22 ES ES99937353T patent/ES2335948T3/en not_active Expired - Lifetime
- 1999-07-22 WO PCT/US1999/016452 patent/WO2000005265A2/en active Application Filing
- 1999-07-22 AT AT99937353T patent/ATE446973T1/en active
- 1999-07-22 EP EP99937353A patent/EP1098908B1/en not_active Expired - Lifetime
- 1999-07-22 EP EP09000493A patent/EP2058333A2/en not_active Withdrawn
- 1999-07-22 DE DE69941598T patent/DE69941598D1/en not_active Expired - Lifetime
-
2001
- 2001-05-29 US US09/866,970 patent/US6458353B1/en not_active Expired - Lifetime
- 2001-06-29 US US09/895,723 patent/US6491915B2/en not_active Expired - Lifetime
- 2001-06-29 US US09/896,309 patent/US6406694B1/en not_active Expired - Lifetime
- 2001-07-03 US US09/898,513 patent/US20030165494A1/en not_active Abandoned
- 2001-07-13 US US09/905,849 patent/US6448021B1/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,847 patent/US6406865B2/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,835 patent/US6395497B1/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,848 patent/US6451522B2/en not_active Expired - Lifetime
-
2003
- 2003-07-14 AU AU2003213475A patent/AU2003213475B2/en not_active Expired
- 2003-09-05 US US10/656,805 patent/US7566539B2/en not_active Expired - Fee Related
-
2004
- 2004-04-16 US US10/826,454 patent/US20040265303A1/en not_active Abandoned
-
2006
- 2006-09-01 AU AU2006206064A patent/AU2006206064B2/en not_active Expired
-
2007
- 2007-04-26 JP JP2007117804A patent/JP2007262074A/en not_active Withdrawn
- 2007-10-25 US US11/924,091 patent/US20080268536A1/en not_active Abandoned
- 2007-10-25 US US11/924,153 patent/US20080241923A1/en not_active Abandoned
- 2007-10-26 US US11/924,794 patent/US7566450B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/924,783 patent/US20090142339A1/en not_active Abandoned
-
2008
- 2008-12-24 JP JP2008328813A patent/JP2009143926A/en active Pending
-
2009
- 2009-03-02 AU AU2009200820A patent/AU2009200820A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019436A1 (en) * | 1994-01-13 | 1995-07-20 | The Regents Of The University Of California | Mammalian monocyte chemoattractant protein receptors |
WO1997031949A1 (en) * | 1996-03-01 | 1997-09-04 | Consejo Superior De Investigaciones Cientificas | Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
Non-Patent Citations (2)
Title |
---|
FRADE J M ET AL: "Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells.", JOURNAL OF IMMUNOLOGY, (1997 DEC 1) 159 (11) 5576-84., XP002126697 * |
FRADE J M R ET AL: "The amino-terminal domain of the CCR2 chemokine receptor acts a coreceptor for HIV-1 infection.", JOURNAL OF CLINICAL INVESTIGATION, (1997 AUG 1) 100 (3) 497-502., XP002099012 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000005265A3 (en) | Anti-crr2 antibodies and methods of use therefor | |
AU3327701A (en) | Humanized anti-ccr2 antibodies and methods of use therefor | |
WO1998018826A3 (en) | Anti-CCR5 antibodies and methods of use therefor | |
MY145191A (en) | Human antibodies that bind human il-12 and methods for producing | |
WO1998031799A3 (en) | Polynucleotides and polypeptides encoding receptors | |
IL156618A0 (en) | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same | |
WO1999037788A3 (en) | Diagnosis and treatment of aur1 and/or aur2 related disorders | |
WO1994016094A3 (en) | Recombinant anti-vla4 antibody molecules | |
AU2821195A (en) | Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin | |
WO2002020569A3 (en) | Mammalian genes; related reagents and methods | |
IL126314A (en) | Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma) | |
WO2001090358A3 (en) | Mammalian receptor proteins; related reagents and methods | |
EP1433792A8 (en) | Human receptor proteins, related reagents and methods | |
CA2068222A1 (en) | Monoclonal antibodies | |
EP0939124A3 (en) | MGBP1 sequences | |
WO2001036467A3 (en) | Mammalian receptor proteins; related reagents and methods | |
WO1999046379A3 (en) | Human receptor proteins; related reagents and methods | |
AU7960600A (en) | Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit | |
WO2000032635A3 (en) | Tumor specific human monoclonal antibodies and methods of use | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
WO2005060368A3 (en) | Humanized anti-ccr2 antibodies and methods of use | |
WO1999035266A3 (en) | Human urotensin ii | |
IL108811A0 (en) | Immunoassay reagents, kits and methods | |
EP0887416A3 (en) | Human AFC1 | |
AU7128098A (en) | Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52208/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/000742 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 561221 Country of ref document: JP Kind code of ref document: A Ref document number: 2336250 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999937353 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999937353 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |